323 related articles for article (PubMed ID: 26048327)
1. Expression, function, and targeting of the nuclear exporter chromosome region maintenance 1 (CRM1) protein.
Ishizawa J; Kojima K; Hail N; Tabe Y; Andreeff M
Pharmacol Ther; 2015 Sep; 153():25-35. PubMed ID: 26048327
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of CRM1-dependent nuclear export sensitizes malignant cells to cytotoxic and targeted agents.
Turner JG; Dawson J; Cubitt CL; Baz R; Sullivan DM
Semin Cancer Biol; 2014 Aug; 27():62-73. PubMed ID: 24631834
[TBL] [Abstract][Full Text] [Related]
3. Nuclear Export as a Novel Therapeutic Target: The CRM1 Connection.
Lu C; Figueroa JA; Liu Z; Konala V; Aulakh A; Verma R; Cobos E; Chiriva-Internati M; Gao W
Curr Cancer Drug Targets; 2015; 15(7):575-92. PubMed ID: 26324128
[TBL] [Abstract][Full Text] [Related]
4. Ribosomal Biogenesis and Translational Flux Inhibition by the Selective Inhibitor of Nuclear Export (SINE) XPO1 Antagonist KPT-185.
Tabe Y; Kojima K; Yamamoto S; Sekihara K; Matsushita H; Davis RE; Wang Z; Ma W; Ishizawa J; Kazuno S; Kauffman M; Shacham S; Fujimura T; Ueno T; Miida T; Andreeff M
PLoS One; 2015; 10(9):e0137210. PubMed ID: 26340096
[TBL] [Abstract][Full Text] [Related]
5. Targeting Nuclear Exporter Protein XPO1/CRM1 in Gastric Cancer.
Sexton R; Mahdi Z; Chaudhury R; Beydoun R; Aboukameel A; Khan HY; Baloglu E; Senapedis W; Landesman Y; Tesfaye A; Kim S; Philip PA; Azmi AS
Int J Mol Sci; 2019 Sep; 20(19):. PubMed ID: 31569391
[TBL] [Abstract][Full Text] [Related]
6. Atomic basis of CRM1-cargo recognition, release and inhibition.
Fung HY; Chook YM
Semin Cancer Biol; 2014 Aug; 27():52-61. PubMed ID: 24631835
[TBL] [Abstract][Full Text] [Related]
7. Nuclear export of proteins and drug resistance in cancer.
Turner JG; Dawson J; Sullivan DM
Biochem Pharmacol; 2012 Apr; 83(8):1021-32. PubMed ID: 22209898
[TBL] [Abstract][Full Text] [Related]
8. Nucleo-cytoplasmic transport as a therapeutic target of cancer.
Gravina GL; Senapedis W; McCauley D; Baloglu E; Shacham S; Festuccia C
J Hematol Oncol; 2014 Dec; 7():85. PubMed ID: 25476752
[TBL] [Abstract][Full Text] [Related]
9. The nuclear export protein exportin-1 in solid malignant tumours: From biology to clinical trials.
Lai C; Xu L; Dai S
Clin Transl Med; 2024 May; 14(5):e1684. PubMed ID: 38783482
[TBL] [Abstract][Full Text] [Related]
10. Anti-tumor activity of selective inhibitor of nuclear export (SINE) compounds, is enhanced in non-Hodgkin lymphoma through combination with mTOR inhibitor and dexamethasone.
Muqbil I; Aboukameel A; Elloul S; Carlson R; Senapedis W; Baloglu E; Kauffman M; Shacham S; Bhutani D; Zonder J; Azmi AS; Mohammad RM
Cancer Lett; 2016 Dec; 383(2):309-317. PubMed ID: 27693556
[TBL] [Abstract][Full Text] [Related]
11. Anti-tumor activity of selective inhibitors of XPO1/CRM1-mediated nuclear export in diffuse malignant peritoneal mesothelioma: the role of survivin.
De Cesare M; Cominetti D; Doldi V; Lopergolo A; Deraco M; Gandellini P; Friedlander S; Landesman Y; Kauffman MG; Shacham S; Pennati M; Zaffaroni N
Oncotarget; 2015 May; 6(15):13119-32. PubMed ID: 25948791
[TBL] [Abstract][Full Text] [Related]
12. Selective Inhibitor of Nuclear Export (SINE) Compounds Alter New World Alphavirus Capsid Localization and Reduce Viral Replication in Mammalian Cells.
Lundberg L; Pinkham C; de la Fuente C; Brahms A; Shafagati N; Wagstaff KM; Jans DA; Tamir S; Kehn-Hall K
PLoS Negl Trop Dis; 2016 Nov; 10(11):e0005122. PubMed ID: 27902702
[TBL] [Abstract][Full Text] [Related]
13. Preclinical activity of a novel CRM1 inhibitor in acute myeloid leukemia.
Ranganathan P; Yu X; Na C; Santhanam R; Shacham S; Kauffman M; Walker A; Klisovic R; Blum W; Caligiuri M; Croce CM; Marcucci G; Garzon R
Blood; 2012 Aug; 120(9):1765-73. PubMed ID: 22677130
[TBL] [Abstract][Full Text] [Related]
14. Novel reversible selective inhibitor of nuclear export shows that CRM1 is a target in colorectal cancer cells.
Niu M; Chong Y; Han Y; Liu X
Cancer Biol Ther; 2015; 16(7):1110-8. PubMed ID: 25996664
[TBL] [Abstract][Full Text] [Related]
15. Antileukemic activity of nuclear export inhibitors that spare normal hematopoietic cells.
Etchin J; Sun Q; Kentsis A; Farmer A; Zhang ZC; Sanda T; Mansour MR; Barcelo C; McCauley D; Kauffman M; Shacham S; Christie AL; Kung AL; Rodig SJ; Chook YM; Look AT
Leukemia; 2013 Jan; 27(1):66-74. PubMed ID: 22847027
[TBL] [Abstract][Full Text] [Related]
16. KPT-330 inhibitor of CRM1 (XPO1)-mediated nuclear export has selective anti-leukaemic activity in preclinical models of T-cell acute lymphoblastic leukaemia and acute myeloid leukaemia.
Etchin J; Sanda T; Mansour MR; Kentsis A; Montero J; Le BT; Christie AL; McCauley D; Rodig SJ; Kauffman M; Shacham S; Stone R; Letai A; Kung AL; Thomas Look A
Br J Haematol; 2013 Apr; 161(1):117-27. PubMed ID: 23373539
[TBL] [Abstract][Full Text] [Related]
17. Selective inhibitors of nuclear export (SINE)--a novel class of anti-cancer agents.
Parikh K; Cang S; Sekhri A; Liu D
J Hematol Oncol; 2014 Oct; 7():78. PubMed ID: 25316614
[TBL] [Abstract][Full Text] [Related]
18. Selinexor, selective inhibitor of nuclear export: Unselective bullet for blood cancers.
Benkova K; Mihalyova J; Hajek R; Jelinek T
Blood Rev; 2021 Mar; 46():100758. PubMed ID: 32972802
[TBL] [Abstract][Full Text] [Related]
19. SINE (selective inhibitor of nuclear export)--translational science in a new class of anti-cancer agents.
Gerecitano J
J Hematol Oncol; 2014 Oct; 7():67. PubMed ID: 25281264
[TBL] [Abstract][Full Text] [Related]
20. Ratjadone and leptomycin B block CRM1-dependent nuclear export by identical mechanisms.
Meissner T; Krause E; Vinkemeier U
FEBS Lett; 2004 Oct; 576(1-2):27-30. PubMed ID: 15474004
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
